Skip to content

Effects of clinical pharmacist interventions on the secondary prevention of coronary heart disease

Effects of clinical pharmacist interventions on the secondary prevention of coronary heart disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16007716
Enrollment
Unknown
Registered
2016-01-06
Start date
2016-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Intervention group:pharmacist advise for life-style and medication regimens face-to-face at the time of discharge of the patients
Intervention group:Pharmacist provides telephone advice at week 1, month 1 and 3 after discharge, emphasized on the therapy, time, location and cost of geting prescriptions, side effects of the medici
Control group:Usual care giving by the nurse and physician

Sponsors

Second Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The first attack of ST-Elevation Myocardial Infarction (STEMI) or Non-STEMI, or unstable angina with evidence of at least a 50% occlusion of 1 or more major coronary arteries, with written informed consent by patients or their family members.

Exclusion criteria

Exclusion criteria: 1. Hospital stay shorter than needed for enrollment; 2. Can not complete follow up of one year expected such as severe heart failure, hepatic insufficiency, renal inadequacy, respiratory failure and malignancy; 3. Cognitively impaired, no self-care ability, communication disorders, inability to participate in a follow-up telephone call; 4. Residence in a hospital or long-term care facility; 5. Allergic or contraindication to the medicines used for secondary prevention of coronary heart disease; 6. Eligible but refused to participate.

Design outcomes

Primary

MeasureTime frame
Mortality (both cardiovascular and non-cardiovascular mortality) and non-fatal cardiovascular events (myocardial infarction, stroke, unexpected percutaneous coronary interventions (PCI) or coronary artery bypass surgery (CABG), and cardiac-related hospital admissions) in the follow-up.;

Secondary

MeasureTime frame
Medication compliance; smoking cessation; body weight, blood pressure, serum glucose, and serum lipids management; adverse drug events, non cardiac-related hospital admissions and cost of secondary prevention of coronary heart disease.;

Countries

China

Contacts

Public ContactXiaofeng Yan
yanxiaofeng0804@sina.com+86 571 87783891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026